PODESTA GROUP, INC. for MILLENNIUM PHARMACEUTICALS INC
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
340B-related issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Medicare/Medicaid MMM
Medicare coverage and reimbursement. H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Budget/Appropriations BUD
FY 2013 budget resolutions. H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Pharmacy PHA
Prescription Drug User Fee Act reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millenium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.